{"id":"W2136344041","doi":"10.1016/s1470-2045(14)70063-4","title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1174,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"Universität Duisburg-Essen; Aarhus Universitet; Universität zu Köln; Universitair Medisch Centrum Groningen; University College London; National Institute for Health and Care Research; Universitaire Ziekenhuizen Leuven, KU Leuven; Canadian Cancer Society Research Institute; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; EORTC Charitable Trust; Aarhus Universitetshospital; Cancer Research UK; Amgen","keywords":"Ifosfamide; Doxorubicin; Soft tissue sarcoma; Medicine; Sarcoma; Oncology; Soft tissue; Chemotherapy; Internal medicine; Surgery; Pathology; Cisplatin","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1118737263595385,"score_gpt":0.4083463554134927,"score_spread":0.2964726290539542,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}